Search Result

Isoforms Recommended:	K-Ras

Results for "

K-Ras

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (23) Amino Acid Derivatives (1) AMPK (4) Antibiotic (1) Apoptosis (53) ATTECs (1) Aurora Kinase (1) Autophagy (13) Bcl-2 Family (6) Biochemical Assay Reagents (1) c-Fms (1) c-Myc (3) Calcineurin (1) Calcium Channel (3) Carnitine Palmitoyltransferase (CPT) (1) Caspase (10) CDK (4) COX (3) Cyclophilin (1) Deubiquitinase (1) Discoidin Domain Receptor (3) DNA/RNA Synthesis (5) Drug Derivative (3) Drug Intermediate (7) Drug Isomer (4) E3 Ligase Ligand-Linker Conjugates (6) Early 2 Factor (E2F) (1) EGFR (5) Epigenetic Reader Domain (2) ERK (46) Farnesyl Transferase (15) Ferroptosis (2) Fluorescent Dye (1) G-quadruplex (5) GLUT (3) HCV (1) HCV Protease (1) HMG-CoA Reductase (HMGCR) (1) HSP (1) ICMT (4) IFNAR (4) IKK (1) Interleukin Related (4) Isotope-Labeled Compounds (13) JAK (2) Keap1-Nrf2 (3) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (8) LYTACs (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (3) MEK (13) Mitochondrial Metabolism (3) Mitosis (1) MMP (4) Molecular Glues (6) mTOR (9) NAMPT (1) NEKs (1) NF-κB (5) NO Synthase (2) Oxidative Phosphorylation (2) p38 MAPK (19) PARP (4) PDK-1 (1) PERK (17) Phosphatase (4) Phosphodiesterase (PDE) (13) Phospholipase (1) PI3K (18) PKA (1) PKC (3) Polo-like Kinase (PLK) (1) Potassium Channel (1) PROTAC Linkers (5) PROTAC-Linker Conjugates for PAC (2) PROTACs (34) Protein Prenyltransferase (1) Proton Pump (1) Raf (16) Ras (416) Reactive Oxygen Species (ROS) (10) Reference Standards (5) Ribosomal S6 Kinase (RSK) (2) SARS-CoV (1) SHP2 (2) Small Interfering RNA (siRNA) (4) SOS1 (31) Src (1) STAT (4) STING (3) STK33 (1) Target Protein Ligand-Linker Conjugates (11) Telomerase (1) TGF-β Receptor (1) Tie (1) TNF Receptor (5) ULK (2) VEGFR (3) Virus Protease (1) Wnt (1) YAP (1) YB-1 (1) β-catenin (2) γ-Glutamyl Transferase (GGT) (1)
By Research Areas:	Cancer (529) Cardiovascular Disease (3) Endocrinology (1) Infection (9) Inflammation/Immunology (15) Metabolic Disease (4) Neurological Disease (5)
Click Chemistry:	Azide (3) Alkynes (32)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

548

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-176523

KRAS G12D-IN-29	Ras	Cancer
KRAS G12D inhibitor 29 (Compound Formula (I)) is an orally active and selective KRAS ^G12D mutant inhibitor. KRAS G12D inhibitor 29 blocks downstream signaling pathways mediated by KRAS ^G12D, suppressing tumor cell proliferation. KRAS G12D inhibitor 29 is promising for research of KRAS ^G12D mutation-related cancers (such as pancreatic cancer, lung cancer, colorectal cancer) .

HY-137497

KRAS inhibitor-9	Ras Apoptosis	Cancer
KRAS inhibitor-9, a potent *KRAS* inhibitor (K_d=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells .

HY-18707

K-Ras(G12C) inhibitor 12	Ras Apoptosis	Cancer
K-Ras(G12C) inhibitor 12 is an irreversible inhibitor of *K-Ras(G12C). K-Ras(G12C) inhibitor 12 can alter the nucleotide-binding preference of K-Ras* and block its interaction with effector proteins. K-Ras(G12C) inhibitor 12 can reduce cell viability and induce apoptosis in lung cancer cell lines with G12C mutations. K-Ras(G12C) inhibitor 12 has anti-tumor activity .

HY-18674

K-Ras-IN-1	Ras	Cancer
K-Ras-IN-1 is the inhibitor for *K-Ras* by occupying the binding site of son of sevenless (Sos), preventing the interaction between Sos and K-Ras, inhibiting the Sos-catalyzed GDP to GTP exchange process. K-Ras-IN-1 is promising for research of pancreatic, colon and lung cancer .

HY-130991

K-Ras ligand-Linker Conjugate 6	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-159652

KRAS inhibitor-31 1 Publications Verification	Ras	Cancer
KRAS inhibitor-31 (compound 33) is a *KRAS* inhibitor, with K_D (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .

HY-144661

KRAS G12D inhibitor 14	Ras Apoptosis	Cancer
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a K_D of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .

HY-151523

KRas G12R inhibitor 1	Ras	Cancer
KRas G12R inhibitor 1 is a covalent inhibitor targeting the common oncogenic mutant KRas G12R with selectivity for the mutant arginine. KRas G12R inhibitor 1 possesses an α,β-diketoamide and exploits strong nucleophilicity of the mutant cysteine and irreversibly binds in the Switch II region of KRas. KRas G12R inhibitor 1 can be researched for K-Ras (G12R)-driven cancer such as pancreatic ductal adenocarcinoma (PDAC) .

HY-122914

KRAS inhibitor-3 1 Publications Verification	Ras	Cancer
KRAS inhibitor-3 is an inhibitor of *KRAS* inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity (K_D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf .

HY-179253

KRAS-IN-47	Ras	Cancer
KRAS-IN-47 is a *KRAS* inhibitor with IC₅₀ < 50 nM against KRAS G12V. KRAS-IN-47 can be used for the study of cancers .

HY-164350

KRAS inhibitor-27	Ras ERK p38 MAPK	Cancer
KRAS inhibitor-27 (Compound 15h) is the inhibitor for *KRAS. KRAS* inhibitor-27 inhibits KRAS G12D/G12V mutated cells AsPC-1, SW620 and KRAS wildtype cell HT-29 with IC₅₀ of 378, 0.6 and 3230 nM, respectively. KRAS inhibitor-27 inhibits ERK phosphorylation (IC₅₀ in cell AsPC-1 and SW620 is 0.6 nM and 1 nM), reduces the expression of DUSP4, thereby inhibiting MAPK signaling pathway .

HY-138295

KRAS inhibitor-10	Ras	Cancer
KRAS inhibitor-10 selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1 .

HY-12446

K-Ras(G12C) inhibitor 9	Ras	Cancer
K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C) .

HY-171255

KRAS G12D inhibitor 26	Ras	Cancer
KRAS G12D inhibitor 26 is a modulator of *Kras, targeting Kras(G12D) with an IC₅₀* ≤ 100 nM .

HY-159474

KRAS inhibitor-24	Ras	Cancer
KRAS inhibitor-24 (compound 115c) is a pyridopyrimidine *KRAS* inhibitor, with an IC₅₀ of < 100 nM for KRas G12V, KRas WT and KRas G12R .

HY-153880

KRAS degrader-1	LYTACs Ras	Cancer
KRAS degrader-1 is a potent *KRAS* degrader. KRAS degrader-1 targets specific proteins for degradation via the autophagy-lysosomal degradation pathway. KRAS degrader-1 is suitable for use in cancer research. (Blue: KRAS G12C-IN-72 (HY-128414); Black: Linker (HY-175587); Pink: 5-Iodoindolin-2-one (HY-76986); Blue + Black: KRAS ligand-Linker Conjugate 7 (HY-175586)) .

HY-177511

KRAS G12D-IN-30	Ras p38 MAPK Raf MEK ERK	Cancer
KRAS G12D-IN-30 (Compound 4) is a *KRAS* inhibitor. KRAS G12D-IN-30 inhibits the activation of the downstream MAPK signaling cascade (Raf1-MEK-ERK) by blocking the activity of the KRAS G12 mutant. KRAS G12D-IN-30 can be used for the research of cancer .

HY-176918

K-Ras ligand-Linker Conjugate 8	Target Protein Ligand-Linker Conjugates Ras	Cancer
K-Ras ligand-Linker Conjugate 8 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for KRAS (HY-162960) and a PROTAC linker, which recruits E3 ligases. K-Ras ligand-Linker Conjugate 8 can be used for synthesis of PROTAC KRAS(on) degrader ACBI-4 (HY-176792) .

HY-128771

K-Ras G12C-IN-4	Ras	Cancer
K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS ^G12C .

HY-169311

KRAS inhibitor-37	Ras	Cancer
KRAS inhibitor-37 (compound 2) is a potent *KRAS* inhibitor with K_Ds of 0.004 nM, 0.041 nM, 0.019 nM and 0.144 nM for KRAS wild type, KRAS G12D, KRAS G12C and KRAS G12V by SPR binding assay, respectively. KRAS inhibitor-37 inhibits cell proliferation with IC₅₀s of <2 nM-14 nM for H358, SW620, PANC08.13 cells, respectively. KRAS inhibitor-37 has the potential for cancer research .

HY-135865

KRAS inhibitor-7	Ras	Cancer
KRAS inhibitor-7 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound B .

HY-P5192

KRAS G12D(8-16)	Ras	Cancer
KRAS G12D 8-16 is a mutant KRAS G12D 8-16 peptide .

HY-18606

K-Ras G12C-IN-3	Ras	Cancer
K-Ras G12C-IN-3 (Compound VI-5) is an irreversible small molecule inhibitor of mutant K-Ras G12C. K-Ras G12C-IN-3 can be used in the research of cancers .

HY-18604

K-Ras G12C-IN-1 1 Publications Verification	Ras	Cancer
K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.

HY-129776

K-Ras ligand-Linker Conjugate 2	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 2 incorporates a ligand for *K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras* ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-129775

K-Ras ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 1 incorporates a ligand for *K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras* ligand-Linker Conjugate 1 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-130991A

K-Ras ligand-Linker Conjugate 6 formate	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 6 formate incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 formate can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-164749

K-Ras-IN-4	Ras	Cancer
K-Ras-IN-4 (compund CP163) is a *K-Ras* inhibitor .

HY-107841

K-Ras(G12C) inhibitor 6	Ras	Cancer
K-Ras(G12C) inhibitor 6 is a selective and irreversible K-Ras ^G12C inhibitor. K-Ras(G12C) inhibitor 6 can be used for the research of lung cancer .

HY-176250

KRAS-IN-43	Ras ERK	Cancer
KRAS-IN-43 (Compound 9) is a pan-KRAS inhibitor with IC₅₀ values of 0.15 μM, 0.14 μM, and 0.47 μM against KRAS ^G12V, KRAS ^G12C and wild-type KRAS, respectively. KRAS-IN-43 disrupts the interaction between KRAS and cRAF, and inhibits ERK phosphorylation. KRAS-IN-43 is promising for research of KRAS mutation-related cancers (such as pancreatic cancer, colorectal cancer, and lung cancer) .

HY-174261

KRAS-IN-5	Ras	Cancer
KRAS-IN-5 (Compound Ex 6) is an orally active and selective inhibitor targeting *KRAS* mutants (including KRAS ^G12D, KRAS ^G12V, KRAS ^WT) with a GNE IC₅₀ value of 1.3 nM against KRAS ^G12D. KRAS-IN-5 blocks tumor cell proliferation by inhibiting KRAS-mediated signaling pathways (e.g., reducing ERK phosphorylation). KRAS-IN-5 is promising for research of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, lung cancer .

HY-179300A

KRAS-IN-48	Ras	Cancer
KRAS-IN-48 (Compound 1-01) is a *KRAS* mutant inhibitor, with K_d values of 2.58 nM and 5.49 μM for KRAS-G12D and KRAS-G12V, respectively. KRAS-IN-48 can be used in the research of cancer .

HY-P11355A

KRAS WT Peptide TFA	Amino Acid Derivatives	Cancer
KRAS WT Peptide TFA is the trifluoroacetate salt of KRAS WT Peptide (HY-P11355). KRAS WT Peptide is the normal sequence peptide of the Kirsten rat sarcoma virus (KRAS) gene without oncogenic mutations. KRAS WT Peptide can be used for the study of evaluating the specificity and safety of KRAS-targeted immunotherapies .

HY-159476

KRAS inhibitor-26	Ras	Cancer
KRAS inhibitor-26 (compound 194a) is a potent KRAS G12V inhibitor (IC₅₀: ≤100 nM). KRAS inhibitor-26 can be used for cancer research .

HY-146544

KRAS inhibitor-14	Ras	Cancer
KRAS inhibitor-14 (compound 3-22) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.249 µM. KRAS inhibitor-14 shows p-ERK inhibition activities with IC₅₀s of 1.12, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-14 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-161066

KRAS G13D-IN-1	Ras	Cancer
KRAS G13D-IN-1 (Compound 41) is a selective and covalently reversible inhibitor of KRAS ^G13D (IC₅₀: 0.41 nM). The selectivity for KRAS ^G13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRAS ^G13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades. KRAS G13D-IN-1 can be used in the research of colon cancer .

HY-P11356

KRAS G12V Peptide	IFNAR	Cancer
KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors .

HY-P11357A

KRAS G12C Peptide TFA	IFNAR	Cancer
KRAS G12C Peptide TFA is the trifluoroacetate salt of KRAS G12C Peptide (HY-P11357). KRAS G12C Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12C oncogenic mutation. KRAS G12C Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12C Peptide can be used for the study of immune responses against KRAS G12C-mutant tumors .

HY-P11356A

KRAS G12V Peptide TFA	IFNAR	Cancer
KRAS G12V Peptide TFA is the trifluoroacetate salt of KRAS G12V Peptide (HY-P11355). KRAS G12V Peptide is a specific peptide derived from the Kirsten rat sarcoma virus (KRAS) gene carrying the G12V oncogenic mutation. KRAS G12V Peptide induces responses like IFN-γ secretion and cytotoxicity. KRAS G12V Peptide can be used for the study of immune responses against KRAS G12V-mutant tumors .

HY-179414

KRAS G12D-IN-34	Ras	Cancer
KRAS G12D-IN-34 (Compound 13) is a KRAS (G12D) inhibitor with IC₅₀ values for KRAS (G12D) and KRAS (WT) of 1.05 nM and 1.59 μM respectively. KRAS G12D-IN-34 can be used for research on non-small cell lung cancer .

HY-18605

K-Ras G12C-IN-2	Ras	Cancer
K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.

HY-130822

K-Ras ligand-Linker Conjugate 4	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 4 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-130823

K-Ras ligand-Linker Conjugate 5	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 5 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-130707

K-Ras ligand-Linker Conjugate 3	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-163594

KRAS-IN-59	Ras	Cancer
K-Ras-IN-58 is a *K-RAS* inhibitor and shows inhibitory activity against KRAS^G12D, KRAS^G12C and KRAS WT. K-Ras-IN-58 inhibits proliferation of cancer cells .

HY-153412

KRAS inhibitor-22	Ras	Cancer
KRAS inhibitor-22 (compound FB9/6B9) is a potent inhibitor of *K-Ras. KRAS* inhibitor-22 targets to Kras 4B(G12D) and (G12C), which can be used for cancer research .

HY-156363

K-Ras-IN-2	Ras	Cancer
K-Ras-IN-2 (Compound CHI-000-667) is a *K-Ras* antagonist, and can be used for tumor research .

HY-173329

KRAS-IN-41	Ras	Cancer
KRAS-IN-41 is an inhibitor of *KRAS* with IC₅₀ values of <0.01 μM for KRAS G12D and KRAS G12V. KRAS-IN-41 inhibits RAS mutant cell lines, GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS-IN-41 can be used in cancer research .

HY-178501

KRAS-IN-45	Ras	Cancer
KRAS-IN-45 (Compound 1.019) is a *KRAS* inhibitor. KRAS-IN-45 can be used for the study of cancers .

HY-178502

KRAS-IN-46	Ras	Cancer
KRAS-IN-46 (Compound 1.013) is a *KRAS* inhibitor. KRAS-IN-46 can be used for the study of cancers .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0735

Phellodendrine chloride 2 Publications Verification	Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Phenols Polyphenols Plants Isoquinoline Alkaloids Disease Research Fields Source Classification Cancer	Autophagy Apoptosis AMPK mTOR STAT Interleukin Related PKC p38 MAPK NF-κB COX Reactive Oxygen Species (ROS) PI3K Akt MMP
Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .

HY-125847

Salvianolic acid F 1 Publications Verification	Stilbenes Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	Ras PI3K Akt Caspase Apoptosis Bcl-2 Family NF-κB MMP
Salvianolic acid F is a *KRAS* inhibitor, especially for *KRAS* G12D. Salvianolic acid F inhibits NF-kB, MMP-9, and NO simultaneously. Salvianolic acid F inhibits cancer cell growth, invasion, and migration and induces apoptosis via the EP300/PI3K/AKT pathway in vitro. Salvianolic acid F inhibits the growth of *KRAS*-dependent lung cancer cells via the PI3K/AKT signaling pathway in vivo. Salvianolic acid F can be used in the research of various cancers, including *KRAS* G12D-driven non-small cell lung cancer (NSCLC) and ovarian cancer .

HY-135700

Mevalonolactone	Structural Classification Microorganisms Other Phenylpropanoids Phenylpropanoids Source Classification	Calcineurin Ras HMG-CoA Reductase (HMGCR)
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of *K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase* in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-N0427

Phellodendrine	Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Phenols Polyphenols Quinoline Alkaloids Plants Inflammation/Immunology Disease Research Fields Source Classification	Akt NF-κB AMPK mTOR PKC STAT Interleukin Related p38 MAPK COX Reactive Oxygen Species (ROS) Apoptosis Autophagy PI3K MMP
Phellodendrine is an orally active plant alkaloid. Phellodendrine inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .

HY-137971

(±)-Spiro-oxanthromicin A	Microorganisms Ketones, Aldehydes, Acids Source Classification	Ras
(±)-Spiro-oxanthromicin A (Compound 4), a polyketide, is a *K-Ras* inhibitor with an IC₅₀ of 26.7  μM. (±)-Spiro-oxanthromicin A can be isolated from soil-derived Streptomyces sp. (±)-Spiro-oxanthromicin A can mislocalize oncogenic mutant K-Ras from the plasma membrane of intact MDCK cells. (±)-Spiro-oxanthromicin A can be used for cancers research .

HY-178224

Morindone	Quinones Structural Classification Morinda citrifolia Linn. Rubiaceae Benzene Quinones Plants Source Classification	Apoptosis DNA/RNA Synthesis
Morindone is an anthraquinone found in Morinda citrifolia L. Morindone can inhibit cancer cells proliferation, induce apoptosis and cause G1 phase arrest. Morindone can inhibit activities of DNA polymerase and downregulate mutated TP53 and KRAS gene expression. Morindone can be used for the research of cancer, such as colon cancer .

HY-N0735R

Phellodendrine chloride (Standard)	Alkaloids Structural Classification Phellodendron amurense Rupr. Rutaceae Phenols Polyphenols Plants Isoquinoline Alkaloids Source Classification	Reference Standards Autophagy mTOR AMPK Apoptosis STAT Interleukin Related PKC p38 MAPK NF-κB COX Reactive Oxygen Species (ROS) PI3K Akt MMP
Phellodendrine chloride (Standard) is the analytical standard of Phellodendrine chloride (HY-N0735). Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway.

HY-120885

(+)-Oxanthromicin	Microorganisms Phenols Polyphenols Source Classification	Ras
(+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy .

HY-112541

21-Hydroxyoligomycin A	Microorganisms Macrolide Antibiotics Antibiotics Source Classification	Ras Antibiotic
21-Hydroxyoligomycin A is a potent inhibitor of K-Ras PM localization with an IC₅₀ value of 4.82 nM. 21-Hydroxyoligomycin A has cytotoxicity and can be isolated from Streptomyces .

HY-N8387

Neogrifolin	Human Gut Microbiota Metabolites Microorganisms Phenols Polyphenols Endogenous metabolite Source Classification	Ras
Neogrifolin is an inhibitor of *KRAS. Neogrifolin suppress KRAS* expression in human colon cancer cells. Neogrifolin has anti-cell viability activity against HeLa, SW480 and HT29 cells wih IC₅₀s of 24.3, 34.6, and 30.1 μM, respectively .

HY-134505

Avicin G	Structural Classification Acacia victoriae Benth. Terpenoids Plants Pentacyclic Triterpenoids Fabaceae Source Classification	Ras NF-κB
Avicin G is a sphingomyelinase inhibitor and plasma membrane disruptor. Avicin G inhibits the enzymatic activities of neutral sphingomyelinases (SMPD2/3) and acid sphingomyelinase (SMPD1), elevates intracellular sphingomyelin levels, and alters the distribution of sphingomyelin. Avicin G interferes with the lateral segregation of GTP- and GDP-bound H-Ras, inhibits the signal output of oncogenic K-Ras and H-Ras, reduces the phosphorylation of ERK and Akt, increases lysosomal pH, and inhibits the endocytic recycling of epidermal growth factor receptor. Avicin G can be used in research related to pancreatic ductal adenocarcinoma and non-small cell lung cancer .

Cat. No.	Product Name	Chemical Structure

HY-176785S

MCB-294

MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with K_ds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC₅₀s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .

HY-179253

KRAS-IN-47
KRAS-IN-47 is a *KRAS* inhibitor with IC₅₀ < 50 nM against KRAS G12V. KRAS-IN-47 can be used for the study of cancers .

HY-114277S

Sotorasib-d7

Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

HY-162445S

KRASG12D-IN-3-d3
pan-KRAS-IN-5-d₃ is deuterated labeled pan-KRAS-IN-5.

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-114436S

MRTX-1257-d6
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .

HY-114277S2

Sotorasib-d3
Sotorasib-d₃ (AMG-510-d₃) is deuterium labeled Sotorasib. Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C?mutated locally advanced or metastatic non?small cell lung cancer (NSCLC) .

HY-160220S

KRAS inhibitor-23
KRAS inhibitor-23 (Isomer 2 of compound i) is a potent inhibitor of KRAS that plays an important role in cancer research .

HY-176355S

KRAS 2A, U-15N
KRAS 2A, U- ¹⁵N is the ¹⁵N-labeled KRAS 2A.

HY-176358S

KRAS 2B G12C mutant, Arg-13C6,15N4, Lys-13C6,15N2
KRAS 2B G12C mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G12C mutant.

HY-176359S

KRAS 2B G12D mutant, Arg-13C6,15N4, Lys-13C6,15N2
KRAS 2B G12D mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G12D mutant.

HY-176354S

KRAS 2B G12V mutant, Arg-13C6,15N4, Lys-13C6,15N2
KRAS 2B G12V mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G12V mutant.

HY-180885S

KRAS G12D-IN-35
KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer .

HY-176356S

KRAS 2B, Arg-13C6,15N4, Lys-13C6,15N4
KRAS 2B, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₄ is the ¹³C- and ¹⁵N-labeled KRAS 2B.

HY-176342S

KRAS 2B Q61H mutant, Arg-13C6,15N4, Lys-13C6,15N2
KRAS 2B Q61H mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B Q61H mutant.

HY-176353S

KRAS 2B G13C mutant, Arg-13C6,15N4, Lys-13C6,15N2
KRAS 2B G13C mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G13C mutant.

HY-176357S

KRAS 2B G12R mutant, Arg-13C6,15N4, Lys-13C6,15N2
KRAS 2B G12R mutant, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G12R mutant.

HY-176341S

KRAS 2B G13D mutant, Arg-13C6,15N4, Lys-13C6,15N2
KRAS 2B G13D mutant, Arg-Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled KRAS 2B G13D mutant.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks